Greenwich LifeSciences Bolsters Flamingo-01 Trial with Additions of Harvard and Johns Hopkins

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has announced the inclusion of Harvard Medical School and Johns Hopkins University in its Phase III clinical trial, Flamingo-01. This strategic move further enhances the credibility and potential success of the trial, which aims to evaluate the safety and efficacy of GLSI-100 in preventing breast cancer recurrences.

The addition of these prestigious institutions brings together a team of highly skilled and experienced researchers and clinicians who can provide valuable insights and guidance throughout the trial. This collaboration can help ensure that the trial is designed and executed effectively, increasing the likelihood of successful outcomes.



The involvement of these institutions also brings access to extensive patient networks, which can help increase the number of eligible patients for the trial. This can lead to faster enrollment and a more diverse patient population, making the results more representative and applicable to a broader range of patients.

Greenwich LifeSciences' partnerships with clinical sites and networks in the US and Europe align with its overall strategy for expanding the trial's reach and accelerating its progress. These partnerships enable the company to increase the number of clinical sites, access specialized expertise and resources, enhance patient recruitment and retention, and facilitate international expansion.

The Flamingo-01 trial is a prospective, randomized, double-blinded, multi-center study designed to evaluate the safety and efficacy of GLSI-100 in HER2/neu positive patients with residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.

Greenwich LifeSciences' strategic partnerships with leading academic institutions like Harvard and Johns Hopkins further strengthen the company's position in the clinical trial landscape and bring it one step closer to developing a potential new treatment option for breast cancer patients. As the trial progresses, investors should closely monitor the developments and consider the potential impact on the company's stock price.